HSPA2 and myelodysplastic syndrome: We hope that the identified four biomarker candidates (AMER1, HSPA2, NCX1, and TNFRSF10C) will clinically facilitate the early identification of AZA resistance, thus avoiding months of potentially futile therapy, and ultimately promote the development of novel strategies for prognostic prediction and personalized therapy for MDS patients.